Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling

Running title: KSHV induces EndMT

Category of publication: Research article

Paola Gasperini,1 Georgina Espigol-Frigole,1 Peter J. McCormick,1 Ombretta Salvucci,1 Dragan Marie,2 Thomas S. Uldrick,3 Mark N. Polizzotto,3 Robert Yarchoan,3 and Giovanna Tosato1

1Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda MD 20892, USA. 2Laboratory of Neurophysiology, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda MD 20892, USA. 3HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda MD 20892, USA

Corresponding author: Georgina Espigol-Frigole, Laboratory of Cellular Oncology, CCR, NCI, NIH; Building 37, Room 4134, Bethesda, MD 20892; E-mail Georgina.Frigole@mail.nih.gov; Fax (301) 594-9585; Phone 301-594-8685.

Research support: intramural research program of CCR/NCI/NIH and NINDS/NIH.

Conflict disclosure: The authors declare no conflict of interest.

Manuscript information: word count text: 5,077; abstract: 208; Figures 7; supplemental figure 1.

Keywords: KSHV, Kaposi’s sarcoma, EndMT, Notch, mesenchymal.
Abstract

Endothelial to mesenchymal transition (EMT) is now widely considered a pivotal contributor to cancer progression. In this study, we show that the Kaposi’s sarcoma-associated herpesvirus (KSHV) is a sufficient cause of EMT, potentially helping to explain the aggressiveness of Kaposi’s sarcoma (KS) that occurs commonly in AIDS patients. Upon KSHV infection, primary dermal microvascular endothelial cells lost expression of endothelial markers and acquired expression of mesenchymal markers, displaying new invasive and migratory properties along with increased survival. KSHV activated Notch-induced transcription factors Slug and ZEB1 and canonical Notch signaling was required for KSHV-induced EMT. In contrast, KSHV did not utilize the TGFβ signaling pathway, which has also been linked to EMT. Within KS lesions, KSHV-infected spindle cells displayed features compatible with KSHV-induced EMT including a complex phenotype of endothelial and mesenchymal properties, Notch activity and nuclear ZEB1 expression. Our results demonstrate that KSHV engages the EMT program to increase the invasiveness and survival of infected endothelial cells, traits that likely contribute to viral persistence and malignant progression. One important implication of our findings is that therapeutic approaches to disrupt the Notch pathway may offer novel approaches for KS treatment.
Introduction

Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, is a gamma herpesvirus discovered in tissue of AIDS-associated Kaposi’s sarcoma (KS), and found to be the etiologic agent of all types of KS. KSHV is also linked to primary effusion lymphoma, a subset of multicentric Castleman’s disease and an IL-6-related inflammatory syndrome in patients with AIDS.

KS is a multicentric angioproliferative disease often localized in the skin. Histologically, KS lesions are complex. The characteristic KS spindle cells are elongated KSHV-infected fibroblast-like cells, which represent the main proliferating cell in the lesions. All KS lesions also contain aberrant small vessels and form slit-like leaky spaces replete with red cells. Infiltration with inflammatory lymphocytes, plasma cells and monocytes is common. KS lesions often transition from a stage where inflammatory and vascular elements are more prominent to a stage in which spindle cells are more prominent.

The origin of the KS spindle cells has been controversial, in part because KS cells express heterogeneous markers. Several studies have concluded that the spindle cells are of endothelial lineage, as they express the vascular endothelial cell markers CD31, CD34, CD36 and others, but the staining for endothelial markers is inconsistent. Other studies have proposed that KS cells derive from mesenchymal precursors or mature pericytes, smooth-muscle cells or fibroblasts as they express smooth-muscle actin. More recently, KS spindle cells have been thought to be of lymphatic endothelial cell lineage because they express LYVE-1, VEGFC and VEGF-R3, markers for the lymphatic endothelium. The difficulty at defining the origins of KS cells is explained in part by studies in vitro showing that KSHV infection causes phenotypic changes in endothelial cells. In vascular endothelial cells, KSHV promotes the expression of
lymphatic markers, and, in lymphatic endothelial cells KSHV promotes the expression of vascular endothelial markers, suggesting that viral infection can re-program endothelial cells.

Endothelial cells display considerable plasticity manifested by the ability to morph (transform) into mesenchymal cells. Endothelial-to-mesenchymal transformation (EndMT), similar to epithelial-to-mesenchymal (EMT) transformation, is critical to certain steps in development and contributes to disease. EndMT is required for endothelial/endocardial cells to form the mesenchymal heart cushion cells that generate portions of the heart septa and valves. In the adult, EndMT contributes to pathological fibrosis in the heart and kidneys, to cancer progression by generating carcinoma-associated fibroblasts, and to heterotopic bone formation in patients with fibrodysplasia ossificans progressiva.

The heterogeneity and evolution of KS tissue biopsies, the uncertainties surrounding the origin and phenotype of KS cells, and the observation that KSHV infection promotes change in gene expression and marker profiles raised the possibility that KSHV reprograms endothelial cells to acquire a mesenchymal phenotype. In this study, we examined the possibility that KSHV is an inducer of EndMT. We report that KSHV infection induces transcriptional, phenotypic and functional changes in endothelial cells consistent with their transformation into mesenchymal-like cells, and that such changes are recapitulated in KS tissues.

Materials and Methods

**Virus production.** rKSHV.219, a recombinant KSHV that expresses the green fluorescent protein (GFP) during latent replication, and the red fluorescent protein (RFP) during lytic replication, was used for all experiments. The construction and production of rKSHV.219 have
been previously published.  

**Cell lines.** EAHY926 cells (ATCC) were maintained in DMEM (GIBCO, Invitrogen) with 10% heat-inactivated fetal bovine serum (FBS) and 1mM glutamine; neonatal human Dermal Microvascular Endothelial Cells (DMVEC, Lonza), were maintained in EBM-2 basal endothelial growth medium supplemented with EGM-2MV bullet kit (Clonetics). Human bone marrow–derived mesenchymal stem cells (BM-MSC; Cambrex BioScience) were propagated in Dulbecco’s-modified Eagle medium, low glucose (Invitrogen) with 10%FBS.

**Tissues.** Biopsies of cutaneous KS lesions were obtained from 8 patients (7/8 patients HIV-positive; 3 stage T0, 5 stage T1; 3 with <50 and 5 with >50 cutaneous lesions; all lesions were nodular) volunteering on protocols in the HIV and AIDS Malignancy Branch of the National Cancer Institute. Skin was obtained from autopsies of cancer patients without HIV infection or KS. The biopsies were utilized fresh or snap-frozen and kept at -80°C until utilized. The Institutional Review Board of the National Cancer Institute approved the protocols; all patients gave written informed consent.

**KSHV infection.** rKSHV.219 (2.5 mL supernatant of virus-producing VERO cells) pre-incubated (30 min, room temperature) with 2μg/ml polybrene was added onto cells in 60mm plates and centrifuged (1 hour; 2500 rpm; 30°C). Viral supernatant was replaced with culture medium after 18 hours; KSHV-infected cells were selected with 0.5μg/ml or 1μg/ml puromycin (Invitrogen).

**Cell culture.** KSHV-infected endothelial cells (48hrs after infection) were cultured in DMEM low glucose, Glutamine 2mM, heparin 2mg/ml and 10% FBS, 48 hours after infection. The γ-secretase inhibitor DAPT N-[N-(3,5-difluorophenacetyl)-L-alanyl]S-phenylglycine t-butyl ester (Sigma-Aldrich) dissolved in dimethylsulfoxide (DMSO) (Sigma-Aldrich) was added to KSHV-
infected (48 hours after infection) and non-infected endothelial cell cultures at the final concentrations of 1, 5, 8 and 10 μM. DMSO (0.1%) was used as vehicle control. Fresh DAPT was added at every culture passage for the length of the 12-day culture.

Adipocyte differentiation. Confluent MSC were subjected to three cycles of induction/maintenance. Each cycle consists of 3-day culture in Adipogenesis Induction medium (Lonza) followed by 1-3 days culture in maintenance medium. Cultures were fixed (10% buffered formalin) and stained with Oil Red O. Bright-field and fluorescence microscopy images were acquired through a Nikon Eclipse E600 microscope equipped with Plan Apo 4×, and photographed with a digital camera (Retiga 1300; QImaging). Images obtained with IPLab for Windows software (Scanalytics) were imported into Adobe Photoshop (Adobe Systems, San Jose, CA).

Immunoblotting. Protein extracts for phosphorylated proteins prepared in SDS lysis buffer with protease inhibitor cocktail setIII (Calbiochem, Darmstadt, Germany), 50 mM NaF, and 1 mM sodium orthovanadate were resolved in NuPAGE 4-12% Bis-Tris Gel or 6% tris-glycine (Invitrogen) and transferred to protran membranes (Whatman GmbH). Antibodies for immunoblotting: smooth muscle actin (1A4; Dako); CD31 (R&D Systems); TGFBRII, Tie-2 and actin (c11) (all from Santa Cruz Biotechnology); and VE cadherin, Vimentin, PDGFRβ, SMAD3 and P-SMAD2/3 (all from Cell Signaling Technologies). Horseradish peroxidase (HRP)–conjugated rabbit anti–goat IgG-Fc was from Calbiochem (La Jolla, CA); and HRP-conjugated donkey anti–mouse IgG and donkey anti–rabbit IgG were from Amersham Pharmacia Biotech. Bound secondary antibodies were visualized by enhanced chemiluminescence (Amersham).

Immunofluorescence. DMVEC cells were grown on Lab-tek chamber slides (Nunc, Thermo Scientific), fixed (cold 4% paraformaldehyde in PBS) and stained with antibodies to Vimentin
(CST); F-actin was detected with Alexa Fluor 568–conjugated antibody to phalloidin (Molecular Probes). KS biopsies (no.8) were fixed (cold 4% paraformaldehyde in PBS), cryoprotected in 15% and 30% sucrose, embedded in OCT, and processed for histology. Sections were immunostained with combinations of the following antibodies: CD31 (R&D Systems), CD146 (BD Pharmingen), PDGFRβ (Cell Signaling Technologies) smooth muscle actin (clone 1A4; Dako), ZEB-1 (clone H102, Santa Cruz Biotechnology), Hey2 (Santa Cruz Biotechnology), ZEB-2 (Bethyl Laboratories) and LANA (ABI). Secondary antibodies were combinations of spectrally-compatible Alexa Fluor-conjugated antibodies (all from Molecular Probes). Nuclei were visualized with DAPI (1:2000; Invitrogen). Confocal microscopy images were acquired using either a Zeiss LSM 510 confocal microscope (Carl Zeiss, Thornwood, NJ) or a Zeiss Axiovert 100M inverted microscope fitted with a 20×/0.3 NA Plan-Neofluar dry objective or a 40×/0.8 NA Plan-Neofluar oil immersion objective. Widefield fluorescence microscopy images were taken using an Axiovert 200M fluorescence microscope (Carl Zeiss) through a ×32 objective and Velocity Acquisition software (Improvision). Images were imported into Adobe Photoshop (Adobe Systems). Fluorescent images were quantified with Image Pro-Plus software (MediaCybernetics, Inc).

**Cell growth assay.** EAHY926 cells were seeded (24,000 cells/well; 24-well plates) in culture medium supplemented with 0.1% FBS. Growth curves were obtained from time-lapse images of live cells obtained every 30 minutes over 50 hours of culture using the IncuCyte system (Essen Instruments).

**Scratch assay.** Confluent cultures of EAHY926 cells in 24-well plates were scratched by using standard protocols and rinsed three times to removed cell debris. Plates were placed in the IncuCyte system and imaged overnight every 30 minutes. Wound closure curves are constructed
automatically from kinetic imaging data points. Each data point represents the average (±SD) wound closure from 3 fields per well in 3 independent wells.

**Chemotaxis assay.** Chemotaxis ibiTreat μ–Slides (ibidi, GmbH) consisting of two reservoirs (40 μl each) separated by a thin channel (for maintenance of a stable chemotactic gradient up to 48 hrs) were used. Non-infected or KSHV-infected EAHY926 or DMVEC cells (4x10^6 and 2x10^6 cells/ml respectively; in a volume of 6 μl) were seeded into the µ-slides channel in medium without serum. Slides were incubated (37°C, 8 hrs) to allow cell attachment. A gradient of chemoattractant was created in the channel by applying a solution of 50ng/ml PDGF-BB (R&D Systems) or 10%FBS medium onto one reservoir. Cells were imaged continuously for 16h using a Zeiss microscope. Images were analyzed using ImageJ 1.38X software (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, USA). Chemotaxis plots of individual cells were generated with the Chemotaxis and Migration Tool (ibidi).

**RNA, microarray analysis and Real-time RT-PCR.** RNA was extracted using TRI Reagent (Molecular Research Center). cRNA synthesis, hybridization with Affymetrix HG133A, and analyses were performed by the Virus Tumor Biology Section of the Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (GEO accession number GSE33984). cDNA was synthesized from 1 μg total RNA (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Foster City, CA). mRNA was measured by real-time PCR with 1 μL cDNA and Taqman PCR Universal Master Mix (Applied Biosystems). Taqman Gene expression probes for the human mRNAs CD31, VE cadherin, NG-2, PDGFRβ, acta2, Hey1, Hey2 and ALK2 were from Applied Biosystems. PCR reaction conditions were those recommended by the manufacturer. The mRNAs of CD34, CD146, SMA, Snail, Slug, Twist, Zeb1 and Zeb2 were measured by real-time PCR with 1 μL cDNA and power Syber green PCR
Master Mix (Applied Biosystems). Primer sequences are: CD34 F: CAT CAC TGG CTA TTT CCT GAT G and CD34 R: AGC CGA ATG TGT AAA GGA CAG; CD146 F: AAG GCA ACC TCA GCC ATG TCG and CD146 R: CTC GAC TCC ACA GTC TGG GAC; ZEB-1 F: GCA CAA CCA AGT GCA GAA GA and ZEB-1 R: GCC TGG TTC AGG AGA AGA TG; ZEB-2 F: CAA GAG GCG CAA ACA AGC and ZEB-2 R: GGT TGG CAA TAC CGT CAT CC; Twist-1 F: AAG AAA CAG GGC GTG GGG CG and Twist-1 R: CCG CTG CCC GTC TGG GAA TC; SNAIL F: GCT GCA GGA CTC TAA TCC AGA and SNAIL R: ATC TCC GGA GGT GGG ATG; SLUG F: TGG TTG CTT CAA GGA CAC AT and SLUG R: GTT GCA GTG AGG GCA AGA A; SMA F: CCA CTA TTG CAA GGA CAC AT and SMA R: CCA ATG AAG GAG GGC TGG AA. Thermal cycling conditions for amplification were set at 50 °C for 30 minutes and 95 °C for 10 minutes, respectively. PCR denaturing was set at 95 °C at 15 seconds and annealing/extension at 60 °C at 60 seconds for 40 cycles. The results were quantified with the comparative C\textsubscript{T} method (known as the 2\textsuperscript{–}[\Delta\Delta C T] method).

**Cytokines measurements.** Human (h)TGFβ1 and hTGFβ2 levels were measured by ELISA (Quantikine, R&D Systems, Minneapolis, MN).

**Statistical analysis.** Group differences were evaluated by 2-tailed Student’s t test. P values less than 0.05 were considered significant.

**Results**

**KSHV represses expression of endothelial markers and increases expression of mesenchymal markers in endothelial cells.** We infected primary dermal microvascular endothelial cells (DMVEC) and the endothelial-like cell line EAHY926 (EAHY) with a recombinant KSHV (rKSHV.219)\textsuperscript{20}. After 12-day culture with puromycin selection achieving
>90% infection (as judged by % GFP+ cells), we examined expression levels of selected endothelial and mesenchymal cell-related markers by quantitative PCR. We used as controls non-infected primary endothelial cells (DMVEC and EAHY), primary bone marrow-derived mesenchymal stem cells (MSC), and endothelial cells (DMVEC and EAHY) cultured in vitro with TGFβ1 (5 ng/ml; 12 days) under conditions reported to promote EndMT. In DMVEC (Figure 1A, representative experiment), KSHV infection reduced mRNA levels of the endothelial markers CD31, VE-cadherin and CD34 similar to the reduction induced by TGFβ1. As a result, levels of expression of CD31, VE-cadherin and CD34 in KSHV-infected DMVEC were comparable to those detected in MSC. KSHV increased mRNA levels of the mesenchymal markers NG-2, PDGFRβ, SMA and acta2 (smooth muscle a-actin) in DMVEC (Figure 1A), which was similar to that achieved by TGFβ1 stimulation or found in MSC. We tested for expression of CD146, a progenitor-type marker expressed in mesenchymal stem cells isolated from multiple organs. We found that KSHV augments somewhat CD146 expression in DMVEC, but the mRNA levels are lower than those detected in MSC or DMVEC cultured with TGFβ1 (Figure 1A). Similar results were derived from EAHY cells, albeit the degree of change induced by KSHV or TGFβ was somewhat lower than in DMVEC (Figure 1B, representative experiment). For comprehensive analysis of changes in gene expression induced by KSHV in EAHY cells, Affymetrix GeneChip arrays were used. These results (Supplementary Table 1, 2 and GEO accession number GSE33984) show that KSHV alters expression of a large number of genes: down-regulates expression of numerous endothelial-related genes and adhesion molecules, and up-regulates expression of genes linked to cell motility and cytoskeleton rearrangement.
By immunoblotting using DMVEC, we found that KSHV infection reduces protein levels of the endothelial markers CD31, VE-cadherin and Tie-2 and increases protein levels of the mesenchymal markers PDGFRβ, SMA and vimentin (Figure 1C). By confocal microscopy, we found the KSHV infection causes an increase and redistribution of polymerized actin, as revealed by phalloidin staining (Figure 1D), and vimentin (Figure 1E). These results indicate that the changes in gene expression induced by KSHV in endothelial cells are consistent with the occurrence of EndMT.

**Functional changes in endothelial cells infected with KSHV.** Mesenchymal cells are locally invasive and can migrate to distant sites; epithelial cells acquire invasive and migratory properties as they transition into mesenchymal cells (EMT). We examined whether endothelial cell reprogramming by KSHV is associated with increased cell motility. Using *in vitro* wound-healing assays, we found that KSHV-infected EAHY cells are significantly more efficient than uninfected EAHY cells at closing the wound (P=0.002 slope curve difference; P=0.02 difference at the 18hr time point; Figure 2 A-C). To test whether these differences are attributable to differences in cell proliferation, we compared cell growth of control and KSHV-infected EAHY cells. KSHV-infected EAHY cells grew at a similar rate as the control non-infected cells up to 30-32 hours of incubation (Figure 2D), suggesting that the difference in wound closure (occurring during this time-frame) is likely attributable to increased cell motility induced by KSHV. Continued observation beyond 32 hours showed that whereas control EAHY cells became significantly less (P<0.05 at time points 43-51hr) confluent ~24 hours after reaching full cell confluency, due to increased cell death, KSHV-infected EAHY maintained full cell confluency over this period and showed little morphological evidence of death (Figure 2D, E). This result is consistent with the observation that KSHV-infected endothelial cells lose
growth contact inhibition \(^9\), and with evidence that resistance to cell death is a characteristic trait acquired during EMT \(^{22,23}\).

We used a modified Boyden chamber assay to evaluate cell migration in response to FBS, selected as a non-specific stimulator of cell movement, and to PDGF, selected as a mesenchymal-selective stimulator of cell movement \(^{24}\). In response to FBS, KSHV-infected EAHY cells migrated less randomly and further toward the stimulant in comparison to non-infected control EAHY cells (Figure 2F). In response to PDGF, KSHV-infected DMVEC migrated mostly selectively toward the stimulant whereas control non-infected DMVEC showed no specific migration (Figure 2G). Thus, KSHV infection promotes increased motility and resistance to cell death in endothelial cells.

Mesenchymal stem cells have self-renewal potential and can differentiate into cells of bone, fat and cartilage lineages \(^{25}\). If KSHV can reprogram cells into mesenchymal cells, such reprogrammed cells would be expected to differentiate into bone, fat and cartilage cells with appropriate stimulation. To test for this, we first induced endothelial cell reprogramming by infecting DMVEC with KSHV, and 12 days after infection we induced osteogenic and adipogenic differentiation. As expected, control MSC from bone marrow differentiated into bone and fat cells over 21 days culture; by contrast, KSHV-infected cells did not (not shown).

Previous studies showed that the KSHV nuclear protein LANA blocks differentiation of 3T3L1 cells into fat cells \(^{26}\). Since KSHV-LANA is expressed in cells infected with KSHV, we examined whether cells reprogrammed by KSHV may be differentiation-inhibited. To this end, we infected with KSHV bone marrow derived MSC and examined their differentiation into fat cells in comparison to uninfected MSC. As expected, uninfected MSC progressively accumulated lipid droplets starting on or about day 10 after culture with adipocyte differentiation
medium (Supplementary Figure A, B). By contrast, KSHV-infected MSC displayed a markedly reduced lipid accumulation throughout the 21-day culture (Supplementary Figure C, D; demonstration of KSHV infection, Supplementary Figure E,F). These results demonstrate that KSHV blocks adipogenic differentiation in MSC, suggesting that KSHV-infected endothelial cells may be similarly impaired.

**Analysis of endothelial and mesenchymal markers in Kaposi Sarcoma tissues.** Since KSHV infection causes reprogramming of endothelial cell *in vitro* resulting in the loss of endothelial cell markers and acquisition of mesenchymal markers, we investigated whether a similar process occurs in KS tissues. Immunofluorescence staining (Figure 3A) shows that the endothelium lining of the capillaries from the normal skin (left panel) and from KS tissue (right panel) stains similarly intensely for CD31 (mean staining intensity 20 and 21 units, respectively). However, KS spindle cells that are LANA⁺ (KSHV-infected) generally display a dimmer CD31 staining in comparison to the capillary endothelium (mean staining intensity 6.6 units). A higher magnification (larger boxed area) allows visualization of the typical, punctate LANA immunostaining.

As markers for mesenchymal cells, we used CD146, PDGFRβ and SMA. Since CD146 is also expressed in the vascular endothelium, we used CD31 co-staining to distinguish between these cell types. In the normal skin the endothelial cells lining blood vessels co-express (co-expression 98%) CD146 and CD31 (Figure 3B). Instead, in KS tissue, CD146 is intensely and broadly expressed by cells that do not stain or stain faintly for CD31, are often LANA⁺ (CD146 and LANA co-expression 96%; CD31, CD146 and LANA co-expression 6.1%) and are not associated with a capillary (Figure 3C). Immunostaining of the normal skin (Figure 3D) revealed that PDGFRβ expression coincides with CD146 expression and marks capillaries.
(CD31, PDGFRβ and CD146 co-expression 95%). Instead, in KS tissue (Figure 3E), PDGFRβ is widely expressed and mostly coincides with LANA and CD146 expression (PDGFRβ, CD146 and LANA co-expression 87%).

SMA is expressed in cells of mesenchymal origin, including vascular smooth muscle cells. In the normal skin (Figure 4A, top panels) SMA and CD31 expression is mostly limited to vessels, with SMA generally surrounding the inner CD31+ endothelium. By contrast, in KS tissue (Figure 4A, bottom panels), SMA expression is broadly detected with or without CD31 expression. Selected areas within various KS biopsies show the presence of occasional KSHV-infected cells that expressed CD31 at high levels but lack expression of SMA (representative fields, Figure 4B), and occasional LANA+ cells that co-expressed CD31 and SMA (Figure 4C). Thus, a proportion of KSHV-infected cells within KS tissues display a mesenchymal-like phenotype; other KSHV-infected cells display an endothelial phenotype and occasionally a transitional endothelial-mesenchymal phenotype.

**Analysis of TGFβ and Notch signaling in KSHV-induced endothelial-mesenchymal transformation.** During cardiac development, the TGFβ/Smad and Notch signaling pathways are implicated in the control of EndMT that accompanies the generation of the mesenchymal cushion cells from endothelial/endocardial cells. Studies in vitro have supported the importance of TGFβ and Notch signaling in EndMT. We examined the potential role of these signaling pathways in EndMT induced by KSHV.

First, we tested whether KSHV infection alters TGFβ secretion by endothelial cells. TGFβ2 was not detected in the conditioned media (36hr conditioning) of DMVEC and EAHY cells infected with KSHV (not shown), whereas TGFβ1 was detected at higher levels in supernatants from KSHV-infected cells compared to uninfected cells (Figure 5A). Since
TGFβ signaling is initiated by the engagement of TGFβ type II receptor (TGFBR2), we tested TGFBR2 protein expression during the time-interval in which KSHV induces EndMT. By immunoblotting (Figure 5B), we observed that TGFBR2 levels oscillate in DMVEC (top panel) and EAHY cells (bottom panel) during 12- to 18- day culture with or without KSHV infection. In general, KSHV-infected endothelial cells displayed lower levels of TGFBR2 than uninfected cells.

To evaluate the potential contribution of TGFβ1/TGFBR2 signaling, we examined the phosphorylation status of the downstream effectors Smad2 and Smad3. We find that the levels of phosphorylated Smad2/3 (P-Smad2/3) are similar in KSHV-infected (9 days post-infection) and uninfected DMVEC and EAHY cells, as are the ratios between P-Smad2/3 and total Smad2/3 (Figure 5C). Furthermore, the Smad3 inhibitor SIS3 31, which inhibited SMAD3 phosphorylation in KSHV-infected endothelial cells, did not prevent KSHV-induced EndMT, as judged by expression levels of endothelial and mesenchymal markers (not shown). These results provide evidence that TGFβ signaling is not critical to KSHV-induced EndMT.

KSHV activates the Notch pathway directly as KSHV-RTA binds to the Notch signaling component RPBj, and indirectly by inducing the Notch ligands Jag1 and Dll4 through KSHV-vFLIP and KSHV-GCPR 32, 33. We investigated the potential contribution of Notch signaling to KSHV-induced EndMT. First, we tested whether Notch signaling is active in KSHV-infected DMVEC by measuring levels of expression of the Notch target genes Hey1 and Hey2 34. We found that expression levels of Hey1 and Hey2 mRNAs were increased in KSHV-infected DMVEC and EAHY cells in comparison to the uninfected controls (Figure 6A). Second, we examined whether KSHV-infected cells within KS tissues have evidence of Notch activation by immunostaining for LANA and Hey2. Fluorescence microscopy images show that Hey2 is
expressed in KS tissue, particularly where LANA is co-expressed (Figure 6B). Third, we tested whether blocking Notch signaling affects KSHV-induced EndMT in endothelial cells, by using the compound DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), which is an inhibitor of γ-secretase, the enzyme that cleaves the intracellular domain of Notch initiating signaling 34. EAHY cells (KSHV-infected or uninfected) were treated with DAPT (5µM throughout the culture period) or left untreated. RNA was extracted at the end of a 12-day culture. DAPT reduced expression of the Notch target genes Hey1 and Hey2 in KSHV-infected EAHY cells, indicative of successful inhibition of Notch signaling. In addition, DAPT reduced expression of the mesenchymal markers NG-2, PDGFRβ, SMA and acta2 in comparison to control cells where Notch signaling was not blocked (Figure 6C). These observations confirm that KSHV induces Notch signaling in endothelial cells, show that KSHV-infected KS lesions have evidence of Notch activation and demonstrate that Notch signaling is a critical contributor to KSHV-induced EndMT.

**Transcription factors expression in KSHV-infected cells and KS tissue.** The transcription factors Slug and Snail play a role in the regulation of EndMT during the development of the cardiac cushion 28,35. Snail was implicated in TGFβ-induced EndMT of human cutaneous microvascular endothelial cells 19. Besides Snail (SNAI1)36 and Slug (SNAI2)37, Twist 38, ZEB1 (δEF1)39 and ZEB2 (SIP1)40 have been linked to EMT. We investigated whether KSHV-induced EndMT is associated with changes in the expression levels of these transcription factors.

Expression of Snail, Slug, Twist, ZEB1 and ZEB2 was consistently increased in DMVEC (Figure 7A) and EAHY cells (Figure 7B) infected with KSHV (12 days post infection) compared to control uninfected cells. In kinetic experiments, ZEB1 and ZEB2 expression was markedly
increased (as much ~500-fold) in DMVEC and EAHY cells 7 days post KSHV infection to the uninfected control cells (not shown). Thus, KSHV regulates expression of transcription factors that have been linked to EndMT or EMT. In additional experiments, we tested whether KSHV promotes expression of these transcription factors acting through Notch. The γ-secretase inhibitor DAPT (10 μg/ml) reduced Slug, ZEB1 and ZEB2 expression induced by KSHV (Figure 9C, ZEB2 expression not shown), but not the expression of Jag1, Jag2, Dll4 or Snail (not shown), providing evidence for a role of Notch signaling in the selective regulation of expression of these transcription factors.

We examined whether ZEB1 is expressed in KSHV-infected cells within KS tissues. Co-staining for LANA and ZEB1 (Figure 7D) showed strong ZEB1 expression in areas of the biopsy where the cells are infected with KSHV, and much lower or no ZEB1 expression in areas of the biopsy where LANA is not detected. A magnification of the KS tissue specimen showed that LANA and ZEB1 are expressed in the same cells within the nuclei (Figure 7F), whereas ZEB1 staining is mostly cytoplasmic in LANA- cells (Figure 7E). The nuclear localization of ZEB1 is consistent with ZEB1 activity in these cells. These results provide evidence for a previously unrecognized link between the transcription factor ZEB1 and EndMT.

Discussion

KSHV is the causative agent of KS, a malignancy characterized by the presence of virus-infected spindle cells, mixed in with inflammatory cells and aberrant slit-like capillaries. The nature of KS spindle cells and exactly how KSHV promotes KS development is still controversial. Here we show that endothelial cells infected with KSHV lose expression of mature endothelial phenotypic markers and acquire phenotypic and functional markers of
mesenchymal cells. We find that this transdifferentiation program is associated with activation of a group of transcription factors linked to EMT, and is critically driven by KSHV-induced Notch signaling. Consistent with these observations, KSHV-infected spindle cells within KS biopsies display a complex and variable phenotype that includes endothelial and mesenchymal cell markers, express the EMT-inducing transcription factor ZEB1 and have evidence of Notch activation. These novel findings clarify the cell source of KS spindle cells and explain the reasons for previous controversy; provide the first example of virus-induced EndMT; and contribute new insights into KS pathogenesis and the mechanisms and potential roles of EndMT.

Activation of Notch signaling was previously reported in KSHV-infected cells \(^{41}\), and was attributed to a direct stimulatory effect by KSHV-RTA \(^{32}\), or to a Jag1/Dll4-mediated effect by vGPCR and vFLIP gene products \(^{33}\), but its role as a mediator of KSHV infection and disease has remained unclear. Notch signaling can regulate the expression of KSHV genes \(^{42}\) and promote quiescence in uninfected cells neighboring the KSHV-infected cells, thus providing a growth advantage to the KS cells \(^{33}\). In this view, KS cells provide the Notch ligands Jag1 and Dll4, which induce Notch signaling in uninfected cells. Other studies using the KS cell lines SLK or KS IMM, which are not infected with KSHV, or using a KSHV-infected, but E6-E7 immortalized lymphatic endothelial cell line suggested that Notch signaling provides a survival advantage to the cells \(^{41,43}\). The current results show that Notch signaling plays a critical role in promoting KSHV-induced EndMT and that this transformation confers on endothelial cells increased motility and resistance to death, a set of traits that likely underline the characteristic ability of KS cells to infiltrate locally. Increased VEGF \(^5\) likely contributes to KSHV-induced EndMT but does not explain the increased cell motility to the mesenchymal-selective pro-
migratory factor PDGF. Interestingly, VEGF contributes to EndMT during heart development.

EndMT is deployed during morphogenesis of the heart enabling endocardial cells (with an endothelial phenotype) to generate the heart cushion cells from which the mesenchymal portion of cardiac septa and valves is formed. Here, the EndMT process results in the generation of terminally differentiated cells. Similarly, the EndMT program has been linked to organ fibrosis, and to ectopic tissue ossification from endothelial cells. In cancer, EndMT was implicated as a source of cancer-associated fibroblasts, which may promote tumor progression by modifying the tumor microenvironment. By contrast, EndMT induced by KSHV reprograms endothelial cells to acquire either a mixed endothelial/mesenchymal phenotype or predominantly mesenchymal phenotype, without progression to mature fibroblasts, fat, cartilage or bone cells. This maturation block is determined by KSHV itself, and it is likely attributable to KSHV-LANA inactivation of GSK-3 (glycogen synthase kinase 3), which regulates key participants in cell differentiation. Consistent with this phenotype, KS lesions do not normally include fibrous, cartilage, bone or fat tissue, and the virus-infected KS cells display a complex endothelial/mesenchymal phenotype that is not encountered in normal tissues. Thus, KSHV-induced EndMT is more similar to EMT occurring in epithelial malignancies in displaying different states of mesenchymal cell differentiation within a tumor. Occasionally, aggressive KS has been associated with “woody” cutaneous edema and fibroma-like nodules. The pathogenesis of these lesions has remained unclear. Our results suggest the possibility that EndMT may lead KS cells to differentiate into fibrous tissue, perhaps in conjunction with loss of viral infection.
TGFβ2 is an inducer of EntMT in development and in mature endothelial cells\cite{18,19,46}, but we find no evidence that TGFβ signaling is deployed in KSHV-induced EndMT. This is consistent with the observation that the TGFβ signaling is blocked in KSHV-infected cells by epigenetic mechanisms\cite{47}. Other factors from the KS microenvironment (perhaps the inflammatory component) may contribute to KSHV-induced EndMT, as KS spindle cells are not fully autonomous, and require growth factors from the microenvironment for growth\cite{5}.

Activation of an EMT program in tumor cells often relies on the interplay between cancer cells and the neighboring stroma\cite{23}, and many factors contribute to EMT, including fibroblast growth factor, hepatocyte growth factor, IL-6, and insulin-like growth factors\cite{22,23}.

Signaling downstream of TGFβ converge in the stimulation of the EndMT-inducing transcription factors Slug and Snail, which coordinate change in lineage marker expression and function\cite{19,35,46}. These and other transcription factors, including ZEB1, ZEB2 and Twist are effectors of EMT\cite{22}. Notch signaling can induce expression of Snail, Slug and ZEB1\cite{28,48,49}. ZEB1 can reciprocally activate Notch signaling, and Snail and Twist cooperate in the regulation of expression and stability of ZEB1 during EMT\cite{50}. We find increased expression of Snail, Slug, Twist, ZEB1 and ZEB2 in KSHV-induced EndMT, and link expression of Snail, ZEB1 and ZEB2 to Notch signaling regulation. ZEB1 is abundant in KS lesions, including the KSHV-infected spindle cells where the nuclear localization is consistent with activity.

In spite of often displaying an indolent clinical course, KS can be aggressive and difficult to manage in patients with AIDS. We find that KS cells have phenotypic traits consistent with EndMT, and that KSHV can induce Notch-dependent EndMT \textit{in vitro}. Mesenchymal transformation likely plays an important role in KS pathogenesis as it does in many cancer types, suggesting that inhibition of Notch signaling should be considered for the treatment of KS.
Acknowledgments

We thank the patients who volunteered for this study; Drs. D. Lowy, M. Boehm, S. Sakakibara, M. Segarra, and K. Jiang for contributions to this work; R. Braveman and L. Li for technical help; K. Aleman and K. M. Wyvill for patient care and organizational aspects of this work.
References


Figure Legends

**Figure 1. Repression of endothelial markers and upregulation of mesenchymal markers in endothelial cells infected with KSHV.** Relative mRNA levels of CD31, VE-cadherin, CD34, CD146, NG-2, PDGFRB, SMA and acta2 in A) DMVEC and B) EAHY926 cell line (EAHY) control (none), infected with KSHV (KSHV), or cultured with TGFβ1 (TGFβ1); mRNA levels were measured by quantitative PCR. RNAs were extracted 12 days after KSHV infection or treatment with 5ng/ml of TGFβ1. RNA from mesenchymal stem cells (MSC) is tested as a control. mRNA levels normalized for GAPDH are expressed as fold change relative to control cells. Experiments are representative of 8 (DMVEC) and 6 (EAHY) performed. C) Cell lysates from control and KSHV-infected DMVEC (12 days after infection) were immunoblotted for CD31, VE cadherin, Tie-2, Vimentin, PDGFRB, SMA proteins and β-actin (loading control). Representative experiment of 3 performed. D) Fluorescence microscopy images of uninfected DMVEC (left panel) and KSHV-infected (12 days post-infection) DMVEC (right panel) stained with phalloidin (red) and DAPI (blue) or E) immunostained for vimentin (red) and DAPI (blue); original magnification 25x.

**Figure 2. KSHV promotes functional change in endothelial cells.** A) Wound closure by KSHV-infected EAHY cells compared to uninfected EAHY cells. Images from scratch assay; original magnification 10x B) Wound closure (% wound area) as a function of time by uninfected (Control) and KSHV-infected (KSHV) EAHY cells. Each data point is the average (±SD) wound closure from 3 fields/well in 3 independent experiments (±SD); C) Mean relative wound closure (± SD) by control and KSHV-infected EAHY at time 0 and 18hr incubation (3 experiments). D) Growth curves of uninfected (control) and KSHV-infected (KSHV) EAHY cells over 48-hr culture (0.1% FBS) from IncuCyte imaging (expressed as % mean (±SD).
confluency (3 fields/well; 3 wells; representative experiment). E) Bright-field images of uninfected and KSHV-infected EAHY (50 hrs after seeding at equal density); original magnification 10x. Chemotaxis of (F) EAHY cells toward FBS (10%) and (G) DMVEC toward PDGF (50ng/ml). Cells where seeded (IBIDI chambers); cell movement was imaged overnight every 10 min. Lines reflect tracks of cells that moved away (red) or toward (black) the chemioattractant; blue dots represent the average movement of the cell population. Representative results from 3 experiments. Cells were used on day 10 post-infection.

**Figure 3. Analysis of CD31, CD146 and PDGFR expression in KS tissues.** A) Fluorescence microscopy images of normal skin tissue (left panel) and KS (stage T1) tissue (right panel) immunostained for CD31 (red) and LANA (green); nuclei are visualized with DAPI (blue). CD31$^{\text{bright}}$ endothelial cells lining vessels are visualized in the normal skin and in KS tissue. The spindle-like cells visualized in the KS tissue (LANA-positive) are typically CD31$^{\text{low}}$ or CD31$^{-}$. Original magnification 32x; the larger boxed panel represents a magnification of the smaller boxed panel. Images from normal skin tissue (B) and KS (stage T1) tissue (C) immunostained for CD146 (pink), CD31 (red) and LANA (green); nuclei are visualized with DAPI (blue). In normal skin, CD31$^{+}$CD146$^{+}$ cells are LANA$^{-}$ and mark endothelial cells lining blood vessels. In KS tissue, the LANA$^{+}$CD146$^{+}$CD31$^{\text{low/neg}}$ cells are widely distributed in the tumor tissue; original magnification 40x; the merged images are magnified in the panel furthest to the right. Normal skin (D) and KS (stage T1) tissue (E) immunostained for PDGFRβ (red), CD146 (pink) and LANA (green); nuclei are stained with DAPI (blue). In normal skin, CD146$^{+}$ PDGFRβ$^{+}$ cells mark vessels and do not express LANA. In KS tissue, CD146$^{+}$PDGFRβ$^{+}$LANA$^{+}$ cells are widely distributed within the tumor tissue. The right panel reflects merged images; the inset reflects a magnification within the panel; original magnification 40x.
Figure 4. Expression of SMA and CD31 in KS tissue and normal skin. A) Fluorescence microscopy images of normal skin (top panels) and KS (stage T0) tissue (lower panels) immunostained for SMA (yellow), CD31 (red) and LANA (green); nuclei are stained with DAPI (blue). In normal skin, SMA⁺CD31⁺ cells mark the vessel wall. In KS tissue, SMA⁺ cells are widely distributed. B) Microscopy images of KS (stage T0) tissue displaying a cluster of CD31bright cells expressing nuclear LANA⁺. C) Microscopy images showing co-expression of SMA (yellow) and low-level CD31 (red) in a LANA⁺ cell. Original magnification of all images, 60x.

Figure 5. Effects of KSHV infection on TGFβ1 secretion and signaling. A) Levels of TGFβ1 were measured by ELISA in supernatants from 36-hr cultures of uninfected or KSHV-infected cells (DMVEC and EAHY). Results are expressed as means (± SD) of two experiments tested in duplicate. B) TGFβ receptor 2 (TGFBR2) in cell lysates of DMVEC (top) and EAHY (bottom) cells at the indicated time-points (d3=day3) after KSHV infection or culture without infection detected by immunoblotting. The membranes were re-probed for actin. Representative experiment of 5 (DMVEC) or 3 (EAHY) performed. C) Phosphorylated (P) SMAD2/3, total SMAD2/3 and actin detected by immunoblotting in cell lysates of DMVEC and EAHY cultured for 9 days with or without infection with KSHV. Representative experiment of 3 performed. The bar graph reflects the mean relative ratios (± SD) of P-SMAD2/3/total SMAD2/3 band intensities detected by immunoblotting in 3 experiments.

Figure 6. KSHV infection promotes the activation of the Notch pathway. A) Expression levels of Hey1 and Hey2 mRNAs in dermal microvascular endothelial cells (DMVEC) and EAHY cells uninfected or infected with KSHV. RNAs were extracted 12 days after KSHV infection or culture without infection. The results from quantitative PCR are expressed as fold
change relative to the uninfected cells. The experiment is representative of 3 performed. **B)** Fluorescence microscopy images of KS (stage T0) tissue immunostained for Hey2 (red) and LANA (green); nuclei are stained with DAPI (blue); original magnification 32x. The inset reflects a magnification showing the co-expression of LANA and Hey2 immunostaining. **C)** Effects of the γ-secretase inhibitor DAPT (5µM throughout the culture period) on the levels of Hey1, Hey2, NG-2, PDGFRB, SMA and acta2 mRNAs in the EAHY926 cells uninfected or KSHV-infected (12-day culture after achieving >90% cell infection as detected by GFP). Representative experiment of 4 performed.

**Figure 7. KSHV infection promotes the expression of SNAIL, SLUG, TWIST, ZEB1 and ZEB2 transcription factors.** RNA was extracted from DMVEC (**A**) and EAHY cells (**B**) cultured (12 days) in medium only or with TGFβ (5ng/ml) or after KSHV infection (~90% cells infected). RNA from mesenchymal stem cells (MSC) was a control. Results reflect fold increase in mRNA (quantitative PCR) relative to control cells after normalization for GAPDH. The results in A and B are representative of 3-5 experiments performed. **C)** Effects of the γ-secretase inhibitor DAPT (10µg/ml) on KSHV-induced expression of SLUG and ZEB1 in EAHY cells (experimental conditions described in the legend to figure 6C). **D)** Images of KS (stage T1) tissue immunostained for ZEB1 (pink) and LANA (green); nuclei are stained with DAPI (blue); original magnification (32X). **E)** Magnification of the inset linked by the arrow showing an area of the tissue where LANA− cells express mostly cytoplasmic ZEB1 staining. **F)** Magnification of the inset linked by the arrow showing an area of KS tissue with LANA+ cells, in which both LANA and ZEB1 are mostly co-expressed in the nuclei; individual stains in E and F are merged in the right panel.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

A

\[ \text{TGFb1 (pg/ml): DMVEC, DMVEC, KSHV, EAHY, EAHY, KSHV} \]

B

\[ \text{TGFBR2, actin: DMVEC, KSHV, d3, d10, d13, d18, EAHY, KSHV, d3, d5, d9, d12} \]

C

\[ \text{P-SMAD 2-3, SMAD 2-3, actin: DMVEC, EAHY, KSHV, KSHV} \]

Figure 5
Figure 6
Figure 7
Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling


Cancer Res  Published OnlineFirst January 11, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-3067

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/01/10/0008-5472.CAN-11-3067.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Permissions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.